Post
The Wall Street Journal
wsj.com
did:plc:i3fhjvvkbmirhyu4aeihhrnv
Boehringer Ingelheim’s top-selling drug lifted sales in the first half, as the German drugmaker gears up to file for U.S. approval of a new obesity medicine. on.wsj.com/4wKx2Hb
https://on.wsj.com/4wKx2Hb
2026-07-15T12:01:49.076Z